Abcellera twitter sentiment
Twitter users discuss $ABCL's GPCR antibody platform, highlighting Tetragenetics acquisition for Tetrahymena high--density expression enabling immune response for targets like NK3R in ABCL635, positioning it as potential validation for zero--to--one tech with Phase 2 data as key catalyst.
Sources
- https://x.com/i/status/2080395122571878863
- https://x.com/i/status/2080421055286362617
- https://x.com/i/status/2080387053267624003
- https://x.com/i/status/2079589362346418222
- https://x.com/i/status/2080399237494211020
- https://x.com/i/status/2079878506134089824
- https://x.com/i/status/2079648857516908735
- https://x.com/i/status/2080418243718611376
- https://x.com/i/status/2079627144033132693
- https://x.com/i/status/2080436852897812649
- https://x.com/i/status/2080382651941220802
- https://x.com/i/status/2080380157143998504
- https://x.com/i/status/2080411586057977950
- https://x.com/i/status/2080396549453140039
- https://x.com/i/status/2080425696329945306
- https://x.com/i/status/2080414783057047807